We are improving our search experience. To check which content you have full access to, or for advanced search, go back to the old search.

Search

Please fill in this field.

Search Results

Showing 1-20 of 4,892 results
  1. HMG-CoA reductase inhibitors and the attenuation of risk for disseminated intravascular coagulation in patients with sepsis

    Background

    Disseminated Intravascular Coagulation (DIC) is a syndrome of dysregulated coagulation. Patients with sepsis are at increased risk for DIC....

    Nicholas B. Alana, William A. Ciurylo, Natalie Hurlock in Journal of Thrombosis and Thrombolysis
    Article 09 November 2023
  2. Effect and mechanism of HMG-CoA reductase inhibitor on the improvement of elderly essential hypertension-induced vascular endothelial function impairment based on the JAK/STAT pathway

    Objective

    Our research was designed to figure out the influence and mechanism of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor...

    Wen Yuan, Hongjun Fan, ... Yong Yan in Diagnostic Pathology
    Article Open access 28 September 2023
  3. Graft protective effects and donor-specific antibody suppression by CD4+CD25+Foxp3+ regulatory T cell induced by HMG-CoA reductase inhibitor rosuvastatin in a murine heart transplant model

    Background

    We previously demonstrated that the hydroxymethylglutaryl-CoA (HMG-CoA) reductase inhibitor (statins) play an important role in the...

    Kazuhito Iguchi, Yasuto Yamamoto, ... Tomoki Shimokawa in Journal of Cardiothoracic Surgery
    Article Open access 25 June 2024
  4. Pitavastatin stimulates retinal angiogenesis via HMG-CoA reductase-independent activation of RhoA-mediated pathways and focal adhesion

    Background

    Excessive angiogenesis of the retina is a key component of irreversible causes of blindness in many ocular diseases. Pitavastatin is a...

    Article 30 July 2021
  5. Potential natural inhibitors of xanthine oxidase and HMG-CoA reductase in cholesterol regulation: in silico analysis

    Background

    Hypercholesterolemia has posed a serious threat of heart diseases and stroke worldwide. Xanthine oxidase (XO), the rate-limiting enzyme in...

    Rishab Marahatha, Saroj Basnet, ... Niranjan Parajuli in BMC Complementary Medicine and Therapies
    Article Open access 01 January 2021
  6. TET2 deficiency sensitizes tumor cells to statins by reducing HMGCS1 expression

    TET2 (ten-eleven-translocation) protein is a Fe(II)- and α-ketoglutarate-dependent dioxygenase that catalyzes DNA demethylation to regulate gene...

    Si-Jia Sun, Ying-Jie Ai, ... Hai-**n Yuan in Oncogene
    Article 08 November 2022
  7. Anti-inflammatory, cytotoxicity and antilipidemic properties: novel bioactivities of true cinnamon (Cinnamomum zeylanicum Blume) leaf

    Background

    The leaf of Ceylon cinnamon (true cinnamon) is traditionally claimed for a variety of health benefits. However, reported scientific...

    Walimuni Prabhashini Kaushalya Mendis Abeysekera, Galbada Arachchige Sirimal Premakumara, ... Walimuni Kanchana Subhashini Mendis Abeysekera in BMC Complementary Medicine and Therapies
    Article Open access 04 October 2022
  8. The effect of atorvastatin on the concentrations of methylglyoxal, glyoxalase 1, and aldo–keto reductase family 1 member B10 in patients with type 2 diabetes mellitus and prediabetes

    Background

    Type 2 diabetes mellitus (T2DM) is often associated with metabolic disorders. Statin drugs are potent inhibitors of cholesterol...

    Ali Nosrati Andevari, Soheila Moein, ... Karimollah Hajian Tilaki in International Journal of Diabetes in Develo** Countries
    Article 28 September 2023
  9. The long-term effect of generic price competition on the Hungarian statin market

    Background

    Generic competition is a vital health policy tool used in regulating the pharmaceutical market. Drug group HMG-CoA reductase...

    Balázs Répásy, Tibor Gazsó, ... Imre Boncz in BMC Health Services Research
    Article Open access 06 May 2023
  10. Drug–Drug Interaction of the Sodium Glucose Co-Transporter 2 Inhibitors with Statins and Myopathy: A Disproportionality Analysis Using Adverse Events Reporting Data

    Introduction

    An increased risk of myopathy due to a potential interaction between sodium glucose co-transporter-2 inhibitors (SGLT-2i) and HMG-CoA...

    Wajd Alkabbani, Ryan Pelletier, ... John-Michael Gamble in Drug Safety
    Article 05 March 2022
  11. Simvastatin Preferentially Targets FLT3/ITD Acute Myeloid Leukemia by Inhibiting MEK/ERK and p38-MAPK Signaling Pathways

    Background

    The FLT3 /ITD mutation exists in many acute myeloid leukemia (AML) patients and is related to the poor prognosis of patients. In this...

    Genhong Li, **gwei Yao, ... Bing Xu in Drugs in R&D
    Article Open access 17 October 2023
Did you find what you were looking for? Share feedback.